Cross-Source Views at the Top and TSO Verification Conclusion
Source 1 (BioSpace press release): Confirms that City Therapeutics closed a $99.5 million Series B financing. New investors include Viking Global Investors and Sofinnova Investments. The funds will accelerate the company’s RNAi engineering platform and pipeline development.
Source 2 (Fierce Biotech): Confirms that City Therapeutics raised a nearly $100 million Series B round, to support clinical advancement and core RNAi platform development. It lists investors including Viking Global Investors, Sofinnova Investments, Casdin Capital, and NYBC Ventures.
Source 3 (BioSpace report): Confirms that City Therapeutics secured $99.5 million in new financing to advance its RNA interference pipeline, and notes that its lead program CITY-FXI is in Phase I clinical trials for thromboembolic diseases.
TSO verification conclusion: The three sources consistently confirm the financing event, the approximate $99.5 million amount, and the use of proceeds for RNAi platform and clinical/pipeline advancement. There are partial differences regarding the investor list and the depth of program description, but these do not affect the core fact that the financing occurred.
Facts Confirmed Across Sources
City Therapeutics completed a Series B financing totaling approximately $99.5 million, also described as “nearly $100 million.”
The use of proceeds is centered on advancing the company’s RNAi / RNA interference platform and clinical pipeline.
At least two sources explicitly mention Viking Global Investors and Sofinnova Investments as participants in the round.
Source 3 specifically says the lead program CITY-FXI is already in Phase I clinical trials.
Main Differences or Points of Divergence
The investor list is not fully consistent
Source 1 only confirms Viking Global Investors and Sofinnova Investments as new investors.
Source 2 additionally names Casdin Capital and NYBC Ventures.
This difference reflects variation in source disclosure and means the full investor list cannot be confirmed from the given sources.
The emphasis in the use-of-proceeds wording differs
Source 1 highlights “accelerating the RNAi engineering platform and pipeline.”
Source 2 emphasizes “clinical advancement” and “core platform development.”
Source 3 focuses on the “RNA interference pipeline” and CITY-FXI.
Disclosure of program stage differs
Only Source 3 states that CITY-FXI is in Phase I clinical trials.
The other sources do not mention this stage, so additional pipeline details cannot be confirmed from the given sources.
Background and Analysis
Taken together, the three sources point to a classic biopharmaceutical financing event: a round close to $100 million, signaling continued investor interest in RNAi and its clinical translation. The common thread across the sources is that City Therapeutics is not merely developing a conceptual platform; it is pushing its RNAi platform and pipeline toward a more defined development stage.
However, based on the sources provided, it is not possible to confirm from the given sources the company’s full pipeline size, all indication areas, pre- and post-money valuation, allocation of proceeds, or whether the round included more detailed milestone conditions.
On the confirmed information alone, the disclosure that CITY-FXI is in Phase I clinical testing indicates that at least one program has entered human trials. Beyond that, other procedural or data-specific details are not fully disclosed across the three sources, so no further inference should be made.
Three-Source Summary
Source 1: Emphasizes that the financing has been completed, with a total of $99.5 million; new investors have joined, and the funds will be used for the RNAi engineering platform and pipeline.
Source 2: Emphasizes that the financing is nearly $100 million and says the funds will support clinical advancement and core RNAi platform work; its investor list is more complete but does not fully match Source 1.
Source 3: Emphasizes that the funds will advance the RNAi pipeline and provides a more specific program update: CITY-FXI is in Phase I clinical trials for thromboembolic disease.
Conclusion
Based on the combined evidence, the fact that City Therapeutics completed an approximately $99.5 million Series B financing in June 2026 can be cross-verified, and the use of proceeds clearly points to RNAi platform and clinical pipeline advancement. As for the full investor list and complete pipeline progress, the given sources contain differences and should be further verified with more comprehensive public materials. Within the current source set, any undisclosed items should be treated as not mentioned by the source or cannot be confirmed from the given sources.